Skip to content
Research/Gene Therapy/AAV9-Follistatin Gene Therapy

AAV9-Follistatin Gene Therapy

AAV9-Follistatin gene therapy involves using an adeno-associated virus (AAV9) vector to deliver the follistatin gene into cells. Follistatin is a protein that inhibits myostatin, a growth factor that limits muscle growth. This therapy aims to enhance muscle mass and strength, which could be beneficial for age-related muscle loss and other muscle-wasting conditions, contributing to improved longevity and healthspan.

Intelligence Profile

Research Papers

Currently, there are no specific research papers directly addressing "AAV9-Follistatin Gene Therapy" in the provided evidence. However, a relevant clinical trial, NCT07443826, is focused on addressing age-related muscle loss using AAV-Follistatin combined with a VEGF plasmid gene therapy. This trial is still in the recruiting phase and spans Phase 1 and Phase 2, suggesting it is in early stages of human testing to evaluate safety and preliminary efficacy.

Since no other studies or trials directly targeting this gene therapy were included in the provided evidence, further conclusions or details specific to AAV9-Follistatin Gene Therapy cannot be drawn from this dataset. It is important to consult broader scientific and clinical databases or literature for more comprehensive information.

Disclaimer: This content is for informational purposes only and not a replacement for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.